Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HI TECH PHARMACAL CO INCv242401_ex99-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported)
December 5, 2011

HI-TECH PHARMACAL CO., INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

No. 0-20424
11-2638720
(Commission File Number)
(IRS Employer Identification No.)

369 Bayview Avenue, Amityville, New York
11701
(Address of Principal Executive Offices)
(Zip Code)

(631) 789-8228
(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  o
   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  o
   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  o
   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  o
   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 
Item 2.02.Results of Operations and Financial Condition.

On December 5, 2011, Hi-Tech Pharmacal Co., Inc. issued a press release announcing its financial results for the second fiscal quarter ended October 31, 2011.  A copy of the press release is attached hereto as Exhibit 99.1 to this current report and is incorporated herein by reference.


Exhibit 9.01.Financial Statements and Exhibits

Exhibit Number
Description
   
Exhibit 99.1
Press Release dated December 5, 2011 of Hi-Tech Pharmacal Co., Inc.


 
2

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   December 5, 2011
  HI-TECH PHARMACAL CO., INC.  
       
 
/s/ David S.  Seltzer  
  Name:    David S. Seltzer  
  Title:   President and Chief Executive Officer  



 
3

 

INDEX TO EXHIBITS





Exhibit Number
 
Description
     
99.1
 
Hi-Tech Pharmacal Co., Inc. Press Release dated December 5, 2011


 
4